# Clinical Study to Evaluate Debio0123 + Sacituzumab Govitecan Combination in TNBC or HR+/HER2- Advanced Breast Cancer

> **NCT06612203** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **MedSIR** · enrollment: 76 (actual)

## Conditions studied

- Advanced Breast Cancer

## Interventions

- **DRUG:** Debio 0123 and Sacituzumab govitecan

## Key facts

- **NCT ID:** NCT06612203
- **Lead sponsor:** MedSIR
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-01-17
- **Primary completion:** 2027-02
- **Final completion:** 2027-10
- **Target enrollment:** 76 (ACTUAL)
- **Last updated:** 2025-12-05

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06612203

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06612203, "Clinical Study to Evaluate Debio0123 + Sacituzumab Govitecan Combination in TNBC or HR+/HER2- Advanced Breast Cancer". Retrieved via AI Analytics 2026-07-10 from https://api.ai-analytics.org/clinical/NCT06612203. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*